Evidence map›Paper›PMID 42498949›Full record

ArticleAllergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology2026

Optimizing conversations on treatment management in hereditary angioedema: healthcare professional and patient perspectives on long-term prophylaxis and shared decision-making.

Markus Magerl, Emel Aygören-Pürsün, Jens Greve, Andreas Recke, Petra Staubach-Renz, Inmaculada Martinez-Saguer, Lucia Schauf, Diane Langenbacher, Danielle Christmas, Tamara Ray and 1 more

Abstract read
In one paragraph

Article in Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Markus MagerlInstitute of Allergology, Charité-Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität Zu Berlin, and Immunology and Allergology, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Berlin, Germany. markus.magerl@charite.de.
Emel Aygören-PürsünDepartment for Children and Adolescents, University Hospital Frankfurt, Frankfurt, Germany.
Jens GreveDepartment of Otorhinolaryngology, Head and Neck Surgery, Ulm University Medical Center, Ulm, Germany.
Andreas ReckeDepartment of Dermatology, University of Lübeck, Lübeck, Germany.
Petra Staubach-RenzDepartment of Dermatology, University Medical Center, Mainz, Germany.
Inmaculada Martinez-SaguerHZRM Hämophilie Zentrum Rhein Main, Gartenstraße 134, 60596, Frankfurt/Main, Germany.
Lucia SchaufHAE Vereinigung E.V. [HAE Association], Aldenhoven, Germany.
Diane LangenbacherMaster Factory for Patient Centric Healthcare GmbH, Neuried, Germany.
Danielle ChristmasResearch Partnership, London, UK.
Tamara RayBioCryst Pharmaceuticals, Inc., Durham, NC, USA.
Sven PohlBioCryst Pharmaceuticals Deutschland GmbH, Munich, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionHereditary angioedema (HAE), characterized by unpredictable attacks of subcutaneous or submucosal edema, can significantly impact patient quality of life (QoL). Despite advances in long-term prophylaxis (LTP), achieving complete control of HAE is challenging, making shared decision-making (SDM) critical for tailored HAE management. This investigation explores the dynamics of healthcare professional (HCP)-patient conversations concerning HAE management, and identifies barriers to SDM, LTP initiation and strategies that may overcome these to optimize patient QoL.

methodsThe investigation was conducted in Germany. HCPs managing patients with HAE participated in 60 min interviews and led simulated patient consultations. 30 min interviews with patients with HAE were also conducted.

resultsTen HCPs and eight patients with HAE were interviewed. In the simulated consultations, most HCPs recommended LTP based on high attack frequency and substantial impact on QoL. Interviews revealed that HCPs typically initiate discussions on LTP by assessing disease burden, focusing on attack frequency and QoL. These treatment discussions also highlighted the need for improved communication with patients about the LTP treatments that are available to them. However, many HCPs lacked awareness of updated treatment guidelines and faced challenges in reassuring patients about the long-term safety and efficacy of newer LTP options. All patients who were initiated on LTP experienced positive results, including improved QoL and reduced fear of attacks. Those who declined LTP cited low attack frequency on their acute treatment and concerns about burden of treatment and long-term effects. Key barriers to effective SDM included time constraints during routine consultations, absence of clear SDM guidance, and a lack of jargon-free information to foster proactive patient engagement.

conclusionThis research highlights opportunities to enhance HCP-patient conversations concerning the management of HAE. Inconsistencies between positive patient experiences with LTP and real-world prescription rates emphasize the need for improved SDM practices. Enhancing HCP awareness of patient perspectives, managing time constraints in consultations, and providing unbiased, patient-friendly information may help bridge these gaps and improve communication and ultimately patient QoL. The findings underscore the importance of further research to develop guidelines that prioritize SDM and patient empowerment in HAE management.

Indexed as

Hereditary angioedemaLong-term prophylaxisShared decision-making

Identifiers

PMID42498949
PMCPMC13401321

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.